--- title: "Anavex Life Sciences (AVXL) news: offering and Nasdaq notice" url: "https://aibio.space/companies/anavex-life-sciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AVXL offering and Nasdaq notice news: Anavex signs at-the-market sales agreement with TD Cowen for up to $150 million. Anavex Life Sciences Corp." --- AVXL Anavex Life Sciences Corp. NASDAQ · United States # Anavex Life Sciences (AVXL) news AVXL offering and Nasdaq notice news Listings · 2026-09-02 ## [Anavex regains Nasdaq compliance after filing overdue 10-Qs on August 28, 2026](https://aibio.space/news/anavex-regains-nasdaq-compliance-after-filing-overdue-10-qs-august-28/) Nasdaq says Anavex has regained compliance after filing overdue quarterly reports, but the release does not say why they were late. ## Latest Anavex Life Sciences news 1. 2026-08-10 Distress [Anavex Life Sciences files NT 10-Q, says June quarter report is late amid special committee review](https://aibio.space/news/anavex-life-sciences-files-nt-10-q-says-june-quarter-report-late-amid/) Anavex (Nasdaq: AVXL) cannot file its 10-Q for the quarter ended June 30, 2026 on time. The company also lists its 10-Q for the quarter ended March 31, 2026 as not yet filed. 2. 2026-08-10 Distress [Anavex Life Sciences says it cannot file its June quarter report on time](https://aibio.space/news/anavex-life-sciences-says-cannot-file-june-quarter-report-time/) The company cites a special committee's review of matters tied to the April 30, 2026 termination of its chief executive. Its quarterly report for the period ended March 31, 2026 is also listed as not filed. 3. 2026-05-11 Distress [Anavex Life Sciences files late-filing notice for 10-Q after CEO termination](https://aibio.space/news/anavex-life-sciences-files-late-filing-notice-10-q-after-ceo/) Anavex Life Sciences told the SEC on May 11, 2026 that it cannot file its first-quarter 10-Q on time. The delay follows the April 30 termination of CEO Christopher Missling, and the company says the review of that termination may take longer than it expects. 4. 2025-07-25 Financings [Anavex signs at-the-market sales agreement with TD Cowen for up to $150 million](https://aibio.space/news/anavex-signs-market-sales-agreement-td-cowen-up-150-million/) The company may sell common stock from time to time but is not obligated to sell any. TD Cowen can earn up to 3.0% in commissions. ## Anavex Life Sciences at a glance - **Ticker**: AVXL - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $118.3 million ### Related companies - [Oncotelic Therapeutics](https://aibio.space/companies/oncotelic-therapeutics/) OTC: OTLC - [Upstream Bio](https://aibio.space/companies/upstream-bio/) NASDAQ: UPB - [Precision BioSciences](https://aibio.space/companies/precision-biosciences/) NASDAQ: DTIL - [REBUS HLDGS INC.](https://aibio.space/companies/rebus-hldgs/) OTC: RBSH - [Nevis Brands](https://aibio.space/companies/nevis-brands/) CSE: NEVI - [Solid Biosciences](https://aibio.space/companies/solid-biosciences/) NASDAQ: SLDB - [Cell Source](https://aibio.space/companies/cell-source/) OTC: CLCS - [Vor Biopharma](https://aibio.space/companies/vor-biopharma/) NASDAQ: VOR ### Also on NASDAQ - [Genenta Science S.p.A.](https://aibio.space/companies/genenta-science-s-p-a/) GNTA - [Evaxion](https://aibio.space/companies/evaxion/) EVAX - [Kailera Therapeutics](https://aibio.space/companies/kailera-therapeutics/) KLRA - [Ligand Pharmaceuticals](https://aibio.space/companies/ligand-pharmaceuticals/) LGND - [CytomX Therapeutics](https://aibio.space/companies/cytomx-therapeutics/) CTMX - [ARS Pharmaceuticals](https://aibio.space/companies/ars-pharmaceuticals/) SPRY ## Anavex Life Sciences annual financials | Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 | |---|---|---| | Research and development | [$37.6 million](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001164/) | [$41.8 million](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001164/) | | Net income (loss) | [-$46.4 million](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001164/) | [-$43.0 million](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001164/) | | Cash from operations | [-$39.0 million](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001164/) | [-$30.8 million](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001164/) | | Cash and equivalents | [$102.6 million](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001164/) | [$132.2 million](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001164/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $118.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Anavex Life Sciences Has Anavex Life Sciences raised money recently? Our latest story on this, dated Jul 25, 2025: "Anavex signs at-the-market sales agreement with TD Cowen for up to $150 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/anavex-signs-market-sales-agreement-td-cowen-up-150-million/). Has Anavex Life Sciences received a Nasdaq deficiency notice? Our latest story on this, dated May 11, 2026: "Anavex Life Sciences files late-filing notice for 10-Q after CEO termination". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/anavex-life-sciences-files-late-filing-notice-10-q-after-ceo/). What is the ticker symbol of Anavex Life Sciences? Anavex Life Sciences Corp. trades under the ticker AVXL on NASDAQ. Where is Anavex Life Sciences listed? Anavex Life Sciences Corp. is listed on NASDAQ. Our directory also records these other listings: GETTEX:12X1; LS:A1411S; LSE:0HFR; LSX:A1411S. What is the SEC CIK of Anavex Life Sciences? The SEC Central Index Key (CIK) for Anavex Life Sciences Corp. is 1314052. Its filings are on SEC EDGAR. How many shares does Anavex Life Sciences have outstanding? 92,696,842 shares as of 2026-08-28, per the cover page of its 10-Q filed 2026-08-28. Which country or territory is Anavex Life Sciences listed under? Our directory records Anavex Life Sciences Corp. under United States. What does Anavex Life Sciences do? Our directory classifies Anavex Life Sciences Corp. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Anavex Life Sciences? The ISIN recorded for Anavex Life Sciences Corp. is US0327973006. Does aibio.space cover Anavex Life Sciences? aibio.space lists Anavex Life Sciences Corp. among 2,820 public biotech companies and publishes its news here as stories appear. Is Anavex Life Sciences profitable? Anavex Life Sciences Corp. reported a net loss of $46.4 million for the fiscal year ended Sep 30, 2025, and used $39.0 million of cash in operations, per its annual report to the SEC. How much does Anavex Life Sciences spend on research and development? $37.6 million in the fiscal year ended Sep 30, 2025, per its annual report. How much cash does Anavex Life Sciences have? $118.3 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Anavex Life Sciences (AVXL) stock news? Our latest story on Anavex Life Sciences, dated Sep 2, 2026: "Anavex regains Nasdaq compliance after filing overdue 10-Qs on August 28, 2026". Nasdaq says Anavex has regained compliance after filing overdue quarterly reports, but the release does not say why they were late. [Source](https://aibio.space/news/anavex-regains-nasdaq-compliance-after-filing-overdue-10-qs-august-28/). How long will Anavex Life Sciences's cash last? From our story of May 11, 2026: The same report says Anavex has had a history of losses and no revenue, which raises a risk regarding its ability to continue as a going concern in the future, and that it had accumulated a deficit of approximately $382 million from inception through September 30, 2025. [Source](https://aibio.space/news/anavex-life-sciences-files-late-filing-notice-10-q-after-ceo/). ## Investor discussion: Anavex Life Sciences Members talk about Anavex Life Sciences (AVXL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Anavex Life Sciences, newest first. Each line links the filing it comes from. 1. 2026-09-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001179/e7909_ex99-1.htm) 2. 2026-08-10 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001031/e7841_nt10q.htm) 3. 2026-07-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1314052/000173112226000957/e7790_8-k.htm) 4. 2026-05-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1314052/000173112226000781/e7667_ex99-1.htm) 5. 2026-05-11 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1314052/000173112226000702/e7626_nt10-q.htm) 6. 2025-07-25 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1314052/000173112225001025/e6731_424b5.htm) 7. 2024-12-23 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1314052/000173112224002041/e6219_10-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AVXL on TradingView](https://www.tradingview.com/symbols/NASDAQ-AVXL/). ## SEC filings and registration - **SEC name**: Anavex Life Sciences Corp. - **CIK**: 1314052 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: AVXL (Nasdaq) - **Fiscal year ends**: September 30 - **Filer category**: Large accelerated filer
Smaller reporting company - **Business address**: 630 5TH AVENUE, NEW YORK, NY, 10111 - **Phone**: 844-689-3939 - **Shares outstanding**: 92,696,842 as of 2026-08-28 (10-Q filed 2026-08-28) - **Former names**: Thrifty Printing Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001351/e8011_8-k.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001348/e8009_8k.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001294/e7977_8-k.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001211/e7928_8-k.htm) filed 2026-09-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001179/e7909_8-k.htm) filed 2026-09-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001167/e7886_10-q.htm) filed 2026-08-28 - [10-Q](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001166/e7885_10-q.htm) filed 2026-08-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1314052/000173112226001143/e7897_8-k.htm) filed 2026-08-25 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001314052), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Anavex Life Sciences Corp. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AVXL, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Anavex Life Sciences Corp. - **Ticker**: AVXL - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US0327973006 - **Other listed symbols**: GETTEX:12X1; LS:A1411S; LSE:0HFR; LSX:A1411S - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-AVXL/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/anavex-life-sciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Anavex Life Sciences (AVXL) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/anavex-life-sciences/